Download PDF
Thromb Haemost 1993; 69(01): 070-076
DOI: 10.1055/s-0038-1651551
Original Article
platelets
Schattauer GmbH Stuttgart

Plasma Lipids and Platelet Membrane Fluidity in Essential Hypertension

Kim Hanh Le Quan Sang
1   Pharmacology, CNRS URA 1482, Necker Medical School, Paris, France
,
Madeleine Mazeaud
1   Pharmacology, CNRS URA 1482, Necker Medical School, Paris, France
,
Catherine Astarie
1   Pharmacology, CNRS URA 1482, Necker Medical School, Paris, France
,
Véronique Duranthon
2   Service de Biochimie, Hôpital Saint-Antoine, Paris, France
,
Fathi Driss
2   Service de Biochimie, Hôpital Saint-Antoine, Paris, France
,
Marie-Aude Devynck
1   Pharmacology, CNRS URA 1482, Necker Medical School, Paris, France
› Author Affiliations
Further Information

Publication History

Received 30 January 1992

Accepted after revision 01 September 1992

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Essential hypertension is often associated with high levels of plasma cholesterol or triglycerides. The relationships between plasma lipids and platelet lipids, membrane fluidity and functions in untreated hypertensive patients were investigated by measuring the fluorescence anisotropies of two fluorescent dyes (DPH and its cationic derivative, TMA-DPH, with different subcellular localization), cytosolic Ca2+ and pH, cyclic AMP content and aggregation to ADP and collagen. Hypercholesterolemia was found to be accompanied by a rise in platelet cholesterol content without changes in TMA-DPH or DPH anisotropies whereas hypertriglyceridemia was associated with a decreased cholesterol to phospholipid molar ratio, a decreased DPH anisotropy and a tendency of the cytosol to alkalinize. These results point out the differences between the effects of an acute cholesterol load and those of chronic hypercholesterolemia on platelet membrane microviscosity and aggregation. They demonstrate a strong association between plasma triglyceride levels and platelet membrane structure.

 

  • References

  • 1 Chobanian AV. Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hypercholesterolemia coexist. Hypertension 1991; 18: 130-131
    CrossrefPubMedGoogle Scholar
  • 2 Cambien F, Jacqueson A, Richard JL, Warnet JM, Ducimetiere P, Claude JR. Is the level of serum triglyceride a significant predictor of coronary death in “normocholesterolemic” subjects? The Paris prospective study. Am J Epidemiol 1986; 124: 624-632
    CrossrefPubMedGoogle Scholar
  • 3 Austin MA. Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. Am J Epidemiol 1989; 129: 249-259
    CrossrefPubMedGoogle Scholar
  • 4 Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-438
    CrossrefPubMedGoogle Scholar
  • 5 Zahavi J, Betteridge JD, Jones NAG, Galton DJ, Kakkar VV. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. Am J Med 1981; 70: 59-65
    CrossrefPubMedGoogle Scholar
  • 6 Aviram M, Brook GJ. The effect of human plasma on platelet function in familial hypercholesterolemia. Thromb Res 1982; 26: 101-109
    CrossrefPubMedGoogle Scholar
  • 7 Colli S, Lombroso M, Madema P, Tremoli E, Nicosia S. Effect of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIA hypercholesterolemia. Biochem Pharmacol 1983; 32: 1989-1993
    CrossrefPubMedGoogle Scholar
  • 8 Tremoli H, Maderna P, Colli S, Morazzoni G, Sirtori M, Sirtori S. Increased platelet sensitivity and thromboxane B2 formation in type-II hyperlipoproteinemic patients. Eur J Clin Invest 1984; 14: 329-333
    CrossrefPubMedGoogle Scholar
  • 9 Strobl-Jäger E, Widhalm K, Sinzinger H. Influence of type IIa, IIb and IV-hyperlipoproteinemia on platelet prostaglandin sensitivity, plasma thromboxane B2 and platelet half-life. Prostagl Leukotr Med 1986; 25: 39-47
    CrossrefPubMedGoogle Scholar
  • 10 Croft KD, Beilin LJ, Vandongen R, Rouse I, Masarei J. Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolaemia. Atherosclerosis 1990; 83: 101-109
    CrossrefPubMedGoogle Scholar
  • 11 Malle E, Gries A, Kostner GM, Pfeiffer K, Nimpf J, Hermetter A. Is there any correlation between platelet aggregation, plasma lipoproteins, apoproteins and membrane fluidity of human blood platelets?. Thromb Res 1989; 53: 181-190
    CrossrefPubMedGoogle Scholar
  • 12 Muller S, Ziegler O, Donner M, Drouin P, Stoltz JF. Rheological properties and membrane fluidity of red blood cells and platelets in primary hyperlipoproteinemia. Atherosclerosis 1990; 83: 231-237
    CrossrefPubMedGoogle Scholar
  • 13 Duhm J, Behr J. Role of exogenous factors in alterations of red cell Na+-Li+ exchange and Na+-K+ cotransport in essential hypertension, primary hyperaldosteronism, and hypokalemia. Scand J Lab Invest 1986; Suppl 180: 83-95
    PubMedGoogle Scholar
  • 14 Williams RR, Hunt SC, Hopkins PN. Familial dyslipidemic hypertension. Evidence form 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. J Am Med Assoc 1988; 259: 3579-3586
    CrossrefPubMedGoogle Scholar
  • 15 Hespel P, Lijnen P, Fagard R, M’Buyamba-Kabangu JR, Van Hoof R, Lissens W, Rosseneu M, Amery A. Changes in erythrocyte sodium and plasma lipids associated with physical training. J Hypertension 1988; 6: 159-166
    PubMedGoogle Scholar
  • 16 Nyrop M, Zweifler AJ. Platelet aggregation in hypertension and the effect of the antihypertensive treatment. J Hypertension 1988; 6: 263-269
    PubMedGoogle Scholar
  • 17 De Clerck F. Blood platelets in human essential hypertension. Agents Actions 1985; 18: 563-580
    PubMedGoogle Scholar
  • 18 Shattil SJ, Anaya-Galindo R, Bennett J, Colman RW, Cooper RA. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 636-643
    CrossrefPubMedGoogle Scholar
  • 19 Valtier D, Guicheney P, Baudouin-Legros M, Meyer P. Platelets in human essential hypertension: in vitro reactivity to thrombin. J Hypertension 1986; 5: 551-555
    PubMedGoogle Scholar
  • 20 Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B2 by platelets in vitro. N Engl J Med 1980; 302: 6-10
    CrossrefPubMedGoogle Scholar
  • 21 Erne P, Bolli P, Burgisser FR, Bühler FR. Correlation of platelet calcium with blood pressure. Effect of an antihypertensive therapy. N Engl J Med 1984; 310: 331-332
    CrossrefPubMedGoogle Scholar
  • 22 Le Quan Sang KH, Levenson J, Simon A, Meyer P, Devynck MA. Platelet cytosolic free Ca2+ concentration and plasma cholesterol in untreated hypertension. J Hypertension 1987; 5 (Suppl. 05) S251-S254
    PubMedGoogle Scholar
  • 23 Locher R, Knorr M, Edmonds D, Neyses L, Vetter W. Influence of cholesterol on intracellular free calcium concentration in human platelets. J Hypertension 1986; 4 (Suppl. 06) S358-S360
    PubMedGoogle Scholar
  • 24 Dimitrov D, Resink TJ, Müller FB, Bühler FR. Altered platelet phosphatidylinositol metabolism in essential hypertension. J Hypertension 1986; 4 (Suppl. 06) S346-S348
    PubMedGoogle Scholar
  • 25 Heagerty AM, Ollerenshaw JD. The phosphoinositide signalling system and hypertension. J Hypertension 1987; 5: 515-524
    CrossrefPubMedGoogle Scholar
  • 26 Kramer RM, Jakubowski A, Vaillancourt R, Deykin D. Effect of membrane cholesterol on phospholipid metablism in thrombin-stimulated platelets. J Biol Chem 1982; 257: 6844-6849
    PubMedGoogle Scholar
  • 27 Shastri KM, Carvalho ACA, Roberts RS. Platelet function and platelet lipid composition in the dyslipoproteinemias. J Lipid Res 1980; 21: 467-472
    PubMedGoogle Scholar
  • 28 Benjamin N, Graham JM, Robinson BF, Wilson RBJ. Cholesterol/phospholipid ratio is increased in the plasma membrane of platelets from patients with primary hypertension. J Hypertension 1988; 6 (Suppl. 04) S706-S707
    PubMedGoogle Scholar
  • 29 Naftilan AJ, Dzau VJ, Loscalzo J. Preliminary observations on abnormalities of membrane structure and function in essential hypertension. Hypertension 1986; 8 (Suppl. 02) II: 174-179
    PubMedGoogle Scholar
  • 30 Le Quan Sang KH, Montenay-Garestier R, Devynck MA. Alterations of platelet membrane microviscosity in essential hypertension. Clin Sci 1991; 80: 205-211
    CrossrefPubMedGoogle Scholar
  • 31 Shattil SJ, Cooper RA. Membrane microviscosity and human platelet function. Biochemistry 1976; 15: 4832-4837
    CrossrefPubMedGoogle Scholar
  • 32 Prendergast FG, Haugland RP, Callahan PJ. 1-[4-(Trimethylamino)phenyl]-6-phenylhexa-1, 3, 5-triene: synthesis, fluorescence properties, and use as a fluorescence probe of lipid bilayers. Biochemistry 1981; 20: 7333-7338
    CrossrefPubMedGoogle Scholar
  • 33 Ellefson RD, Caraway WT. Blood lipids. In: Fundamentals of Clinical Chemistry. Trietz NW. (ed). WB Saunders Co; Philadelphia, PA: 1982: 509-510
    Google Scholar
  • 34 Le Quan Sang KH, Devynck MA. Increased platelet cytosolic free calcium in essential hypertension. J Hypertension 1986; 4: 564-574
    PubMedGoogle Scholar
  • 35 Astarie C, Levenson J, Simon A, Meyer P, Devynck MA. Platelet cytosolic proton and free calcium concentrations in essential hypertension. J Hypertension 1989; 7: 485-491
    CrossrefPubMedGoogle Scholar
  • 36 Mazeaud MM, Le Quan Sang KH, Devynck MA. Platelet cyclic AMP in essential hypertension. J Hypertension 1989; 7: 501-506
    CrossrefPubMedGoogle Scholar
  • 37 Muggli R, Tschopp TB, Mittelholzer E, Baumgartner HR. 7-bromi-1,5-dihydro-3,6-dimethylimidazo(2,1-b)quinazolin-2(3H)-one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase. J Pharmacol Exp Ther 1985; 235: 212-219
    PubMedGoogle Scholar
  • 38 Born GVR. Aggregation of blood platelets by adenosine and its reversal. Nature 1962; 195: 927-935
    CrossrefPubMedGoogle Scholar
  • 39 Levin RI, Weksler BB, Jaffe EA. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function. Circulation 1982; 66: 1299-1307
    CrossrefPubMedGoogle Scholar
  • 40 Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509
    PubMedGoogle Scholar
  • 41 Rouser G, Fleischer S, Yamamoto A. Two dimensional thin layer chromatography separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-496
    CrossrefPubMedGoogle Scholar
  • 42 Aviram M, Brook JG. Platelet interaction with high and low density lipoproteins. Atherosclerosis 1983; 46: 259-268
    CrossrefPubMedGoogle Scholar
  • 43 Shinitzky M. Membrane fluidity and cellular functions. In: Physiology of Membrane Fluidity. Shinitzky M. (ed). CRC Press Inc; Boca Raton, FL: 1984. 1 1-51
    Google Scholar
  • 44 Aviram M, Williams KJ, Deckelbaum RJ. Macrophage cholesterol removal by triglyceride-phospholipid emulsions. Biochem Biophys Res Commun 1988; 155: 709-713
    CrossrefPubMedGoogle Scholar
  • 45 Berlin E, Bhathena SJ, Judd JT, Nair PP, Jones DY, Taylor PR. Dietary fat and hormonal effects on erythrocyte membrane fluidity and lipid composition in adult women. Metabolism 1989; 38: 790-796
    CrossrefPubMedGoogle Scholar
  • 46 Mazeaud M, Driss F, Le Quan Sang KH, Duranthon V, Levenson J, Simon A, Devynck MA. Biochemical and functional alterations associated with hypercholesterolemia in platelets from hypertensive patients. Atherosclerosis 1992; 94: 201-211
    CrossrefPubMedGoogle Scholar
  • 47 Astarie C, Le Quan Sang KH, David-Dufilho M, Devynck MA. Further investigations on platelet cytosolic alkalinization in essential hypertension. J Hypertension 1992; 10: 849-854
    PubMedGoogle Scholar